The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Late-Breaking Abstract Session Spans the Realm of Drug-Related Research

Late-Breaking Abstract Session Spans the Realm of Drug-Related Research

January 25, 2021 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—The late-breaking abstract session at ACR Convergence covered a range of clinical trial results, from the use of tocilizumab for COVID-19 to mavrilimumab for remission of giant cell arteritis. Here’s a summary of various study findings shared during the session.

You Might Also Like
  • ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront
  • Submit Your Late-Breaking, High-Impact Rheumatology Studies Now
  • FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis
Explore This Issue
February 2021
Also By This Author
  • State of the Art Session Reviews Lupus Causes, Potential Treatments

Tocilizumab for COVID-19
The use of tocilizumab, an interleukin-6 receptor blockade, did not prevent mechanical ventilation or death in patients who were moderately ill with COVID-19, reported John H. Stone, MD, MPH, professor of medicine, Harvard Medical School and the Edward A. Fox Chair in Medicine at Massachusetts General Hospital, Boston.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In a randomized, double-blind, placebo-controlled trial, 243 hospitalized patients with confirmed SARS-CoV2 infection were randomized 2:1 to standard care plus intravenous tocilizumab 8 mg/kg or placebo.1 The primary outcome was the time to mechanical ventilation or death within 28 days. The study took place from April to June 2020.

For progression to intubation or death, the hazard ratio was 0.83 in the treatment group; for disease worsening, the hazard ratio was 1.11. At 14 days, disease worsening had occurred in 18% of the tocilizumab patients vs. 14.9% of the placebo patients. Also at 14 days, 24.6% of tocilizumab patients still needed oxygen vs. 21.2% in the placebo group. Those treated with tocilizumab experienced fewer serious infections.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Twelve percent of patients in the study were intubated or died, Dr. Stone said.

One-third of patients in the trial had received remdesivir, and fewer than 10% received glucocorticoids.

Results from the trial were published in the Oct. 21 issue of the New England Journal of Medicine.2

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Mavrilimumab Reduces Time to Flare
Mavrilimumab worked better than placebo for controlled time to flare and sustained remission at week 26 in a phase 2 trial with giant cell arteritis (GCA) patients, reported Maria C. Cid, MD, of the Department of Internal Medicine, Hospital Clinic, Barcelona.

The randomized, double-blind, placebo-controlled trial included 70 patients with active new onset or relapsing refractory GCA.3 Patients were randomized 3:2 to receive mavrilimumab 150 mg (n=42) or placebo (n=28) subcutaneously every two weeks, as well as a protocol-defined 26-week prednisone taper that started at 20 to 60 mg/day.

By week 26, disease flare occurred in 19% and 46.4% of patients receiving mavrilimumab and placebo, respectively. Researchers could not estimate the median time to flare by week 26 in the treatment group because too few events occurred. Sustained remission occurred in 83.2% of patients in the treatment group and 49.9% in the placebo group by week 26. The drug was well tolerated.

Pages: 1 2 3 | Single Page

Filed Under: ACR Convergence, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2020, diffuse cutaneous systemic sclerosis, giant cell arteritis (GCA), mavrilimumab, tocilizumab, Tofacitinib, VIG7734, ZiritaxestatIssue: February 2021

You Might Also Like:
  • ACR/ARHP Annual Meeting 2012: Late-Breaking Abstracts Bring Newer Research to the Forefront
  • Submit Your Late-Breaking, High-Impact Rheumatology Studies Now
  • FDA Considers Tocilizumab for GCA & Piclidenoson Enters Phase 3 Trial for RA, Psoriasis
  • GCA Relapse Possible When Discontinuing Tocilizumab

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)